A single-centre , double-blind , randomised placebo-controlled Phase I study evaluated the safety and tolerability of a single oral dose of the second generation RV3-BB rotavirus vaccine ( 8.310 ( 6 ) FFU/mL ) in 20 adults , 20 children and 20 infants ( 10 vaccine and 10 placebo per age cohort ) .
